We investigated the influence of iron or erythropoietin treatment on hemoglobin mass, exercise performance, and acute mountain sickness (AMS) during a 14-day exposure to 3,094 m. With the given drug doses of iron [Fe(III)-hydroxide sucrose 200 mg, 2 times over 4 wk] and erythropoietin (epoetin alfa 50 IU/kg, 3 times/wk for 3 wk), we observed no differences in hemoglobin mass, aerobic exercise performance, or symptoms of AMS between groups relative to a placebo.